The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Sugarbaker EV. Patterns of metastasis in human malignancies. Cancer Biol Rev 2:235, 1981.
Weiss L Gilbert HA, Bone Metastasis: 1981, Boston: G.K. Hall.
Liotta LA Stetler-Stevenson WG, Principles of molecular cell biology of cancer: Cancer Metastasis., in Cancer, Principles & Practice of Oncology, VT DeVita, S Hellman, and S.A. Rosenberg, Editors. 1993, Lippincott Co.: Philadelphia. p. 134–149.
Delaisse J-M Vaes G: Mechanism of mineral solubilisation and matrix degradation in osteoclastic bone resorption, in Biology and Physiology of the Osteoclast. B.R. Rifkin and C.V. Gay, Editors. 1992, CRC Press: Raton, Florida, p. 290–314.
Talhouk RS, Bissell MJ Werb Z: Coordinated expression of ECM-degrading proteinases and their inhibitors regulates mammary epithelial function during involution. J Cell Biol 118:1271–1282, 1992.
Agren MS, Jorgensen LN, Andersen M, et al: Matrix metalloproteinase 9 level predicts optimal collagen deposition during early wound repair in humans. Brit J Surgery 85:68–71, 1998.
Gruber BL, Sorbi D, French DL, et al: Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clinical Immunol Immunopathol 78:161 171, 1996.
Tyagi SC: Proteinases and myocardial extracellular matrix turnover. Molecular and Cellular Biochemistry 168:1–12, 1997.
Gross J Lapiere CM: Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA 48:1014–1022, 1962.
Aimes RT Quigley JP: Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and *-length fragments. J Biol Chem 270:5872–5876, 1995.
Matrisian L: Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6:121–125, 1990.
Rooprai HK, McCormick D: Proteases and their inhibitors in human brain tumours: a review. Anticancer Res 17:4151–4162, 1997.
Celentano DC, Frishman WH: Matrix metalloproteinases and coronary artery disease: a novel therapeutic target. J Clin Pharmacol 37:991–1000, 1997.
Toth M, Gervasi DC, Fridman R: Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells. Cancer Res 57:3159–3167, 1997.
Miyake H, Yoshimura K, Hara I, et al: Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines. J Urology 157:2351–2355, 1997.
Kanno N, Nonomura N, Miki T, et al: Effects of epidermal growth factor on the invasion activity of the bladder cancer cell line. J Urology 159:586–590, 1998.
Lamoreaux WJ, Fitzgerald MEC, Reiner A, et al: Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvascular Res 55:29–42, 1998.
Song SY, Nomizu M, Yamada Y, et al: Liver metastasis formation by laminin-1 peptide (LQVQLSIR)-adhesion selected B16 — F10 melanoma cells. Int J Cancer 71:436–441, 1997.
Tyagi SC, Kumar GS, Glover G: Induction of tissue inhibitor and matrix metalloproteinase by serum in human heart-derived fibroblast and endomyocardial endothelial cells. J Cell Biochem 58:360–371, 1995.
Bafetti LM, Young TN, Itoh Y, et al: Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhanced cellular invasion by melanoma cells. J Biol Chem 273:143–149, 1998.
Haas TL, Davis SJ, Madri JA: Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J Biol Chem 273:3604–3610, 1998.
Qian X, Tuszynski GP: Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc Soc Exp Biol Med 212:199–207, 1996.
Qian X, Wang TN, Rothman VI, et al: Thrombospondin-1 modulates angiogenesisin vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells. ExpCell Res 235:403–412, 1997.
Sorsa T, Salo T, Koivunen E, et al: Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem 272:21067–21074, 1997.
Tyagi SC, Kumar S, Katwa L: Differential regulation of extracellular matrix metalloproteinase and tissue inhibitor by heparin and cholesterol in fibroblast cells. J Mol Cell Cardiology 29:391–404, 1997.
Mazzieri R, Masiero L, Zanetta L, et al: Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 16:2319–2332, 1997.
Okada Y, Morodomi T, Enghild JJ, et al: Matrix metalloproteinase 2 from human rheumatoid synovial fibroblast: purification and activation of the precursor and enzymatic properties. Eur J Biochem 194:721–730, 1990.
Sato H, Seiki M: Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. J Biochem (Tokyo) 119:209–215, 1996.
Cawston TE, Inhibitors of metalloproteinases, inProteinase inhibitors, A.J. Barret and G. Salveson, Editors. 1986: Amersterdam. p. 589–610.
Gomez DE, Alonso DF, Yoshiji H, et al: Tissue Inhibitors of metalloproteinases: structure, regulation and biological functions. Europ J Cell Biol 74:111–122, 1997.
Kossakowska AE, Urbanski SJ, Edwards DR: Tissue inhibitor of metalloproteinases (TIMP-1) RNA is expresses at elevated levels in malignant non-Hodgkin’s lymphomas. Blood 77:12475–12481, 1991.
Brian J, Wang Y, Smith MR, et al: Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP-3). Carcinogenesis 9:1805–1811, 1996.
Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1:27–31, 1995.
Folkman J: Tumor angiogenesis: therapeutic implications. [Review]. New Engl J Med 285:1182–1186, 1971.
Pluda JM: Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Seminars in Oncology 24:203–218, 1997.
Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260–1270, 1997.
Moses MA: The regulation of neovascularization by matrix metalloproteinases and their inhibitors. Stem Cells 15:180–189, 1997.
Zucker S, Mirza H, Conner CE, et al: Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells — conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Internat J Cancer 75:780–786, 1998.
Karelina TV, Goldberg GI, Eisen AZ: Matrix metalloproteinases in blood vessel development in human fetal skin and in cutaneous tumors. J Invest Dermatol 105:411–417, 1995.
Taraboletti G, Garofalo A, Belotti D, et al: Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87:293–298, 1995.
Braunhut SJ, Moses MA: Retinoids modulate endothelial cell production of matrix-degrading proteases and tissue inhibitors of metalloproteinases (TIMP). J Biol Chem 269:13472–13479, 1994.
Vacca A, Moretti S, Ribatti D, et al: Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. Eur J Cancer 33:1685–1692, 1997.
Itoh T, Tanioka M, Yoshida H, et al: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58:1048–1051, 1998.
Vu TH, Shipley JM, Bergers G, et al: MMP-9/Gelatinase B is a Key Regulator of Growth Plate Angiogenesis and Apoptosis if Hypertropic Chondrocytes. Cell 93:411–422, 1998.
Chu YW, Yang PC, Yang SC, et al: Selection of Invasive and Metastatic Subpopulation from a Human Lung Adenocarcinoma Cell Line. Amer J Resp Cell Mol Biol 17:353 360, 1997.
MacDougall JR, Bani MR, Lin Y, et al: The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: Suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res 55:4174–4181, 1995.
Ueda Y, Imai K, Tsuchiya H, et al: Matrix metalloproteinase 9 (gelatinase B) is expressed in multinucleated giant cells of human giant cell tumor of bone and is associated with vascular invasion. Amer J Pathol 148:611–622, 1996.
Kossakowska AE, Hinek A, Edwards DR, et al: Proteolytic activity of human non-Hodgkin’s lymphomas. Amer J Pathol 152:565–576, 1998.
Llorens A, Vinyals A, Alia P, et al: Metastatic Ability of MXT Mouse Mammary Subpopulations Coorelates with Clonal Expression and/or Membrane-Association of Gelatinase A. Molecular Carcinogenesis 19: 54–56, 1997.
Koshiba T, Hosotani R, Wada M, et al: Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 82:642–50, 1998.
Deryugina EI, Luo GX, Reisfeld RA, et al: Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. Anticancer Res 17:3201–3210, 1997.
Koop S, Khokha R, Schmidt EE, et al: Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 54:4791–4797, 1994.
Zeng ZS, Guillem JG: Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases. Bri J Cancer 72:575–582, 1995.
Tomita T: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in thyroid C-cells and medullary thyroid carcinomas. Histopathology 31:150–6, 1997.
Afzal S, Lalani EN, Poulsom R, et al: MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Human Pathol 29:155–165, 1998.
Harada T, Arii S, Mise M, et al: Membrane-type matrix metalloproteinase-1 (MT1-MMP) gene is overexpressed in highly invasive hepatocellular carcinomas. J Hepatology 28:231–239, 1998.
Menashi S, Dehem M, Souliac I, et al: Density-dependent regulation of cell-surface association of matrix metalloproteinase-2 (MMP-2) in breast-carcinoma cells. Internat J Cancer 75:259–265, 1998.
Endo K, Maehara Y, Baba H, et al: Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res 17:2253–2258, 1997.
Gohji K, Fujimoto N, Hara I, et al: Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 79:96–101, 1998.
Kanayama H, Yokota K, Kurokawa Y, et al: Prognostic Values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 82:1359–1366, 1998.
Alvarez OA, Carmichael DF, DeClerck YA: Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 82:589–595, 1990.
DeClerck YA, Perez N, Shimada H, et al: Inhibition of invasion and metastasis in cell transfected with an inhibitor of metalloproteinases. Cancer Res 52:701–708, 1992.
Tsuchiya Y, Sato H, Endo Y, et al: Tissue inhibitor of metalloproteinase 1 is a negative regulator of the metastatic ability of a human gastric cancer cell line, KKLS, in the chick embryo. Cancer Res 53:1397–1402, 1993.
Matsuzawa K, Fukuyama K, Hubbard SL, et al: Transfection of an invasive human astrocytoma cell line with a TIMP-1 cDNA: modulation of astrocytoma invasive potential. J Neuropathol Exp Neurol 55:88–96, 1996.
Hoyhtya M, Hujanen E, Turpeenniemi-Hujanen T, et al: Modulation of type-IV collagenase activity and invasive behavior of metastatic human melanoma (A2058) cells in vitro by monoclonal antibodies to type-IV collagenase. Int J Cancer 46:282–286, 1990.
French DL, Ramos-Desimone N, Rozinski K, et al: Matrix metalloproteinase-9 in tumor cell invasion. Ann NY Acad Sci 732:324–334, 1994.
Chirivi RGS, Garofalo A, Crimmin MJ, et al: Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58:460–464, 1994.
Aparicio T, Kermorgant S, Dessiner V, et al: Matrix Metalloproteinase inhibition prevents peritoneal carcinomatosis development and prolongs survival in rats. Carcinogenesis 20:1445–1451, 1999.
Steward WP: Marimastat (BB2516): current status of development. Cancer Chemotherapy and Pharmacology 43 Suppl.: 556–560, 1999.
Rosemurgy A, Harris J, Langleben A, et al: Marimastat, a novel metalloproteinase inhibitor in patients with advanced carcinoma of the pancreas. 1996. Philadelphia.
Rosemurgy A, Harris J, Langleben A, et al: Marimastat in patients with advanced pancreatic cancer: a dose finding study. Amer J Clin Oncol 22:247–252, 1999.